

eSupplement


eTable 1 Employment status of patients from Spain compared with other countries at enrollment in IOS

	Spain	Other Countries
	n = 119	n = 907
Employment status		
Patients with data, n	97	641
Status, n (%)		
Employed	61 (62.9)	357 (55.7)
Self-employed	1 (1.0)	36 (5.6)
Unemployed	9 (9.3)	46 (7.2)
Retired	5 (5.2)	70 (10.9)
Student	21 (21.6)	91 (14.2)
Homemaker	5 (5.2)	22 (3.4)
Leave of absence/sabbatical	0	5 (0.8)
Preschool	0	5 (0.8)
Other	1 (1.0)	25 (3.9)


IOS, Icatibant Outcome Survey

eFig. 1 a Enrollment rate in IOS from 2009–2018 (cumulative patients) and **b** years of follow-up in IOS in Spain vs other countries. IOS, Icatibant Outcome Survey


a



b




eFig. 2 Median time to diagnosis, by year of birth, in patients from Spain vs other countries




Patients, n	Before 1950	1950 to 1954	1955 to 1959	1960 to 1964	1965 to 1969	1970 to 1974	1975 to 1979	1980 to 1984	1985 to 1989	1990 to 1994	1995 to 1999	2000 Onward
Spain	9	7	6	11	11	11	13	11	9	10	7	0
Other countries	64	40	45	66	69	83	80	72	84	66	38	17

eFig. 3 Proportions of patients with icatibant-treated attacks and treated attacks with other treatment per year in **a** Spain and **b** other countries. 2009 and 2019 were excluded because data were not collected for full years. Patients could be included in either treatment category




eFig. 4 Evolution per year of self-administered icatibant for the treatment of HAE attacks in patients in Spain vs other countries. 2009 and 2019 were excluded because data were not collected for full years. HAE, hereditary angioedema




Attacks, n	2010	2011	2012	2013	2014	2015	2016	2017	2018
Spain	3	19	46	82	81	134	150	235	199
Other countries	43	169	270	337	594	626	712	686	325


eFig. 5 Icatibant treatment outcomes over time from IOS initiation in July 2009 to data cutoff in January 2019. Lines within box plots represent median time in hours, lower and upper lines of boxes represent the 25th and 75th percentiles, and box whiskers denote the minimum and maximum



eFig. 6 Time to icatibant treatment by patient/attack characteristics in patients in Spain vs other countries



eFig. 7 Proportions of patients reporting use of LTP medications per year in Spain vs other countries. 2009 and 2019 were excluded because data were not collected for full years. Counts and percentages are based on patient-reported LTP use during that year. The denominators count all patients in IOS follow-up at any time during the year who do not have LTP with start and end dates missing. IOS, Icatibant Outcome Survey; LTP, long-term prophylaxis



Patients ^a	2010	2011	2012	2013	2014	2015	2016	2017	2018
Spain	10/16	38/56	37/63	42/75	42/75	38/75	38/76	52/94	59/104
Other countries	61/163	107/255	151/335	209/446	226/499	236/530	251/559	290/665	312/737